Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PPBT logo PPBT
Upturn stock ratingUpturn stock rating
PPBT logo

Purple Biotech (PPBT)

Upturn stock ratingUpturn stock rating
$2.27
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: PPBT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $34

1 Year Target Price $34

Analysts Price Target For last 52 week
$34 Target price
52w Low $1.94
Current$2.27
52w High $9.9

Analysis of Past Performance

Type Stock
Historic Profit -73.65%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.13M USD
Price to earnings Ratio -
1Y Target Price 34
Price to earnings Ratio -
1Y Target Price 34
Volume (30-day avg) 1
Beta -0.58
52 Weeks Range 1.94 - 9.90
Updated Date 08/29/2025
52 Weeks Range 1.94 - 9.90
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -45.9

Earnings Date

Report Date 2025-08-14
When Before Market
Estimate -0.21
Actual -0.4

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -10.27%
Return on Equity (TTM) -8.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 188503
Price to Sales(TTM) 58.08
Enterprise Value 188503
Price to Sales(TTM) 58.08
Enterprise Value to Revenue 33.08
Enterprise Value to EBITDA -0.15
Shares Outstanding 2648200
Shares Floating 541350147
Shares Outstanding 2648200
Shares Floating 541350147
Percent Insiders -
Percent Institutions 1.89

ai summary icon Upturn AI SWOT

Purple Biotech

stock logo

Company Overview

overview logo History and Background

Purple Biotech Ltd., formerly Kitov Pharma, is a clinical-stage company focused on developing first-in-class therapies. It was founded in 2010 and has evolved its pipeline through internal development and acquisitions, focusing on oncology.

business area logo Core Business Areas

  • Oncology Drug Development: Developing and commercializing oncology drugs for solid tumors and hematological malignancies.

leadership logo Leadership and Structure

The leadership team includes experienced executives in drug development and finance. The company operates with a structure typical of small biotech firms, with focus on R&D and clinical trials.

Top Products and Market Share

overview logo Key Offerings

  • CM24: A monoclonal antibody targeting CEACAM5, currently in clinical trials for solid tumors. Market share is not applicable as it's not commercialized. Competitors in the CEACAM5 targeting space are companies developing antibody-drug conjugates (ADCs) or other therapies targeting this pathway.
  • NT219: A small molecule targeting IRS1/2, currently in clinical trials for solid tumors. Market share is not applicable as it's not commercialized. Competitors are companies developing inhibitors or modulators of the insulin receptor signaling pathway.

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and growing market, driven by an aging population and advancements in cancer therapies. The market is highly competitive, with numerous companies developing novel treatments.

Positioning

Purple Biotech is a clinical-stage biotech company attempting to develop innovative therapies. They are niche players targeting specific pathways. Their competitive advantage, if any, is based on the novelty and efficacy of their investigational drugs.

Total Addressable Market (TAM)

The TAM for oncology therapeutics is estimated to be hundreds of billions of dollars. Purple Biotech targets niche indications; if CM24 and NT219 succeed, they would capture a small fraction of the overall TAM.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates (CM24 and NT219)
  • Experienced leadership team
  • Focus on specific oncology targets

Weaknesses

  • Clinical-stage company with no approved products
  • Limited financial resources
  • High risk of clinical trial failure

Opportunities

  • Successful clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new oncology indications

Threats

  • Clinical trial failures
  • Competition from other oncology drugs
  • Regulatory hurdles
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • PFE
  • AZN

Competitive Landscape

Purple Biotech is a very small player compared to major pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety with its investigational drugs.

Growth Trajectory and Initiatives

Historical Growth: Growth is measured by progression of clinical trials and securing financing. No product revenue yet.

Future Projections: Future growth depends on successful clinical trial outcomes, partnerships, and regulatory approvals. Analyst estimates are not available to generate at this time.

Recent Initiatives: Focus on advancing CM24 and NT219 through clinical trials. Exploring potential partnerships.

Summary

Purple Biotech is a clinical-stage company with no products on the market. Its valuation is almost entirely based on future expectations that its pipeline drugs pass trials and make it to market. This is speculative in nature. The company must successfully navigate clinical trials and raise capital for continued operations. Strong clinical data are needed.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Press releases
  • Third-party financial databases

Disclaimers:

This analysis is based on available information and is not financial advice. Investments in biotech companies are highly speculative and involve significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Purple Biotech

Exchange NASDAQ
Headquaters -
IPO Launch date 2015-11-20
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 9
Full time employees 9

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.